30 April 2020

Safety Updates on Health Products & Devices

Reference: CIR-2019-00000155

To all health facilities / all health care practitioners in Dubai's private health sector:

Referring to the above subject, DHA notes all health facilities regarding the Circular issued by the MOHAP for information and adhere to what is stated

• Safety update of a pharmaceutical product Actemra / RoActemra (Tocikizumab) 
• Safety update of a pharmaceutical product Benlysta (Belimumab)
• Alerts on the use of E- Cigarette
• Warning from using herbal product Lotus Flower Capsule
• Warning from using herbal product Magnum XXL Capsule
• Warning from using herbal product X Power 3 Tablet
• Safety alert for the medical device Automatic Transport Ventilators
• Removal of Suspension of registration import & marketing of Amoclan Suspension
• Suspend importation & recall of pharmaceutical product Phenylephrine 10mg
• Recall all batches & Suspend importation of Quinine Dihydrochloride 300mg/2ml inj

 

Thanks in advance for your good co-operation

Drug Control Section

Health Regulation Sector

DHA

Supporting Documents:

إضافة تحذير على المستحضر الدوائي Actemra RoActemra (Tocikizumab.pdf:

View Document

إضافة تحذير على المستحضر الدوائي Benlysta (Belimumab).pdf:

View Document

Circular - 1.pdf:

View Document

تحذير من استخدام مستحضر عشبي Lotus Flower Capsule.pdf:

View Document

تحذير من استخدام مستحضر عشبي Magnum XXL Capsule.pdf:

View Document

تحذير من استخدام مستحضر عشبي X Power 3 Tablet.pdf:

View Document

تقرير سلامة للوسيلة الطبية Automatic Transport Ventilators.pdf:

View Document

Amoclan Suspension.pdf:

View Document

Phenylephrine 10mg.pdf:

View Document

Quinine Dihydrochloride 300mg2ml inj.pdf:

View Document